PMID- 21417772
OWN - NLM
STAT- MEDLINE
DCOM- 20110901
LR  - 20211020
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Print)
IS  - 1471-2598 (Linking)
VI  - 11
IP  - 6
DP  - 2011 Jun
TI  - Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years 
      after.
PG  - 763-73
LID - 10.1517/14712598.2011.566855 [doi]
AB  - INTRODUCTION: The first series of patients with metastatic renal cell carcinoma 
      (RCC) treated by non-myeloablative allogeneic hematopoietic cell transplantation 
      (HCT) was reported in 2000 and demonstrated an allogeneic graft-versus-tumor 
      (GVT) effect that encouraged further investigation of this approach. However, the 
      past 10 years have also witnessed profound changes in the medical management of 
      metastatic RCC with the introduction of targeted therapies directed against VEGF 
      or mammalian target of rapamycin (mTOR) signaling pathways creating uncertainty 
      about a continued role for allogeneic HCT in the treatment of RCC. AREAS COVERED: 
      A total of 21 published reports describing clinical outcomes for 398 patients 
      with metastatic RCC treated by allogeneic HCT compiled herein provide a composite 
      overview of the world wide experience for key efficacy and toxicity outcomes. 
      Review of correlative studies that identify donor-derived T cells as mediators of 
      RCC-specific GVT effects offers insight into both the potential as well as the 
      technical barriers to the delivery of antigen-specific post-transplant cellular 
      therapy or vaccination designed to augment the allogeneic GVT effect. EXPERT 
      OPINION: The future development of non-myeloablative allogeneic HCT for 
      metastatic RCC will require novel treatment protocols designed to augment and 
      sustain post-transplant GVT effects against RCC to generate renewed enthusiasm 
      for this approach.
FAU - Tykodi, Scott S
AU  - Tykodi SS
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 
      98109, USA. stykodi@fhcrc.org
FAU - Sandmaier, Brenda M
AU  - Sandmaier BM
FAU - Warren, Edus H
AU  - Warren EH
FAU - Thompson, John A
AU  - Thompson JA
LA  - eng
GR  - K08 CA121912/CA/NCI NIH HHS/United States
GR  - K08 CA121912-05/CA/NCI NIH HHS/United States
GR  - P01 CA078902/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20110321
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
SB  - IM
MH  - Carcinoma, Renal Cell/*surgery
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Kidney Neoplasms/*surgery
MH  - Transplantation, Homologous
MH  - Treatment Outcome
PMC - PMC3201801
MID - NIHMS325784
EDAT- 2011/03/23 06:00
MHDA- 2011/09/02 06:00
PMCR- 2012/06/01
CRDT- 2011/03/23 06:00
PHST- 2011/03/23 06:00 [entrez]
PHST- 2011/03/23 06:00 [pubmed]
PHST- 2011/09/02 06:00 [medline]
PHST- 2012/06/01 00:00 [pmc-release]
AID - 10.1517/14712598.2011.566855 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2011 Jun;11(6):763-73. doi: 10.1517/14712598.2011.566855. 
      Epub 2011 Mar 21.